- Home
- AMBO vs NLSP Comparison
AMBO vs NLSP Comparison
Compare AMBO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- NLSP
- Stock Information
- Founded
- AMBO 2000
- NLSP 2015
- Country
- AMBO United States
- NLSP Switzerland
- Employees
- AMBO N/A
- NLSP N/A
- Industry
- AMBO Other Consumer Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- NLSP Health Care
- Exchange
- AMBO Nasdaq
- NLSP Nasdaq
- Market Cap
- AMBO 6.0M
- NLSP 6.2M
- IPO Year
- AMBO 2010
- NLSP 2021
- Fundamental
- Price
- AMBO $2.18
- NLSP $1.81
- Analyst Decision
- AMBO
- NLSP
- Analyst Count
- AMBO 0
- NLSP 0
- Target Price
- AMBO N/A
- NLSP N/A
- AVG Volume (30 Days)
- AMBO 528.7K
- NLSP 2.2M
- Earning Date
- AMBO 12-30-2024
- NLSP 10-18-2024
- Dividend Yield
- AMBO N/A
- NLSP N/A
- EPS Growth
- AMBO N/A
- NLSP N/A
- EPS
- AMBO N/A
- NLSP N/A
- Revenue
- AMBO $7,839,000.00
- NLSP N/A
- Revenue This Year
- AMBO N/A
- NLSP N/A
- Revenue Next Year
- AMBO N/A
- NLSP N/A
- P/E Ratio
- AMBO N/A
- NLSP N/A
- Revenue Growth
- AMBO N/A
- NLSP N/A
- 52 Week Low
- AMBO $1.00
- NLSP $1.73
- 52 Week High
- AMBO $6.30
- NLSP $20.80
- Technical
- Relative Strength Index (RSI)
- AMBO 48.94
- NLSP 40.38
- Support Level
- AMBO $1.77
- NLSP $1.87
- Resistance Level
- AMBO $2.29
- NLSP $2.08
- Average True Range (ATR)
- AMBO 0.36
- NLSP 0.20
- MACD
- AMBO -0.06
- NLSP 0.01
- Stochastic Oscillator
- AMBO 26.81
- NLSP 2.33
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.